对于患有肠道营养不耐受症的重症儿童的阿莫西西林 (AmoxENI研究):一项随机对照试验
Rania G Abdelatif1, Abanob A Francis1, Elsayed Abdelkreem1
1Department of Pediatrics, Faculty of Medicine, Sohag University, Sohag, Egypt.
氨基显著改善了重症儿童的肠道营养不耐受. 这种治疗导致了更好的营养摄入量和更少的胃肠道症状,表明了潜在的治疗作用.
科学领域:
- 儿科重症监护医药 儿科重症监护医药
- 临床药理学 临床药理学
- 胃肠病学 胃肠病学
背景情况:
- 肠道营养不耐受 (ENI) 是儿科重症监护室 (PICU) 的一个常见挑战.
- 有效的ENI管理对于改善患者的治疗结果至关重要.
- 临床试验.gov 标识符:NCT05828758.8.gov 临床试验.gov 标识符:NCT05828758.gov 临床试验.gov 临床试验.gov 临床试验.gov 临床试验.
研究的目的:
- 评估阿莫西西林在治疗入院于PICU的儿童中ENI的疗效.
- 评估阿莫西西林对营养摄入量和胃肠道症状的影响.
主要方法:
- 一项随机对照试验,涉及90名儿童 (1个月至12岁) 接受ENI治疗.
- 参与者通过胃管每天三次接受阿莫西西林 (10毫克/公斤) 或安慰剂,持续一周.
- 主要结局:在治疗后的第7天,达到≥2/3的能量需求而没有显著的胃肠道症状.
主要成果:
- 阿莫西西林组在75.6%的患者中实现了主要结果,而安慰剂组为31.1% (RR:2.4,p<0.001).
- 氨基显著增加了肠道营养摄入量 (60%比24%,p<0.001),并减少了吐和腹.
- 在组间的其他次要结果中没有发现显著差异.
结论:
- 阿莫西西林在改善重症儿童的ENI方面表现有前途.
- 需要进一步的研究来确认发现,探索机制,并评估临床效用.
更多相关视频
11:17Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
08:33Quantitative Polymerase Chain Reaction-based Analyses of Murine Intestinal Microbiota After Oral Antibiotic Treatment
Published on: November 17, 2018
相关概念视频
Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube...
Enteral Nutrition I: Orogastric and Nasogastric Feeding
Orogastric (OG) and nasogastric (NG) feeding are two standard methods used for enteral nutrition. Enteral nutrition is often preferred over...
Parentral Nutrition: Centeral and Peripheral Parental Nutrition
PN can be administered through two primary routes:
1. Central Parenteral Nutrition (CPN):
CPN involves delivering a high concentration of nutrients through a large vein. This is typically achieved using a Peripherally Inserted Central Catheter (PICC) or,...
Drug Delivery: Enteral Route
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Tonsillitis II: Management
